Table 1. Patients’ background characteristics.
| Characteristic | Total (n = 82), % | PTX/CDDP/RT (n= 41), % | S-1/CDDP/RT (n= 41),% | P value |
|---|---|---|---|---|
| Age(years) | 0.823 | |||
| age < 58 | 35 (42.7) | 18 (43.9) | 17 (41.5) | |
| age ≥ 58 | 47 (57.3) | 23 (56.1) | 24 (58.5) | |
| Gender | 0.532 | |||
| Female | 12 (14.6) | 5 (12.2) | 7 (17.1) | |
| Male | 70 (85.4) | 36 (87.8) | 34 (82.9) | |
| ECOG Performance Status | 1.000 | |||
| 0–1 | 58 (70.7) | 29 (70.7) | 29 (70.7) | |
| 2 | 24 (29.3) | 12 (29.3) | 12 (29.3) | |
| T Stage | 0.659 | |||
| T3 | 40 (48.8) | 21 (51.2) | 19 (46.3) | |
| T4 | 42 (51.2) | 20 (48.8) | 22 (53.7) | |
| N Stage | 0.656 | |||
| N0 | 46 (56.1) | 24 (58.5) | 22 (53.7) | |
| N1 | 36 (43.9) | 17 (41.5)) | 19 (46.3) | |
| M Stage | 0.627 | |||
| M0 | 58 (70.7) | 30 (73.2) | 28 (68.3) | |
| M1a | 24 (29.3) | 11 (26.8) | 13 (31.7) | |
| Clinical Stage (AJCC 2002) | 0.787 | |||
| Stage II | 25 (30.5) | 12 (29.3) | 13 (31.7) | |
| Stage III | 33 (40.2) | 18 (43.9) | 15 (36.6) | |
| Stage IVa | 24 (29.3) | 11 (26.8) | 13 (31.7) | |
| Tumor Location | 0.811 | |||
| Upper-third | 38 (46.3) | 19 (46.3) | 19 (46.3) | |
| Middle-third | 30 (36.6) | 16 (39.0) | 14 (34.1) | |
| Lower-third | 14 (17.1) | 6 (14.7) | 8 (19.6) | |
| Histological Differentiation | 0.890 | |||
| Well differentiated | 19 (23.2) | 10 (24.4) | 9 (22.0) | |
| Fairly differentiated | 37 (45.1) | 19 (46.3) | 18 (43.9) | |
| Poorly differentiated | 26 (31.7) | 12 (29.3) | 14 (34.1) | |
| Tumor Length (cm) | 1.000 | |||
| < 5 | 32 (39.0) | 16 (39.0) | 16 (39.0) | |
| ≥ 5 | 50 (61.0) | 25 (61.0) | 25 (61.0) | |
| Weight Loss in 6 months | 0.810 | |||
| ≤ 10% | 57 (69.5) | 29 (70.7) | 28 (68.3) | |
| > 10% | 25 (30.5) | 12 (29.3) | 13 (31.7) |
Abbreviations: n: number of patients; PTX: Paclitaxel: CDDP: Cisplatin; RT: radiotherapy; ECOG: Eastern Cooperative Oncology Group. Upper: including cervical and upper thoracic portion; Middle: Mid-thoracic portion; Lower: including lower thoracic and distal esophagus.